Literature DB >> 8333965

High-level expression of secreted proteins from cells adapted to serum-free suspension culture.

D T Berg1, D B McClure, B W Grinnell.   

Abstract

We have developed a host cell/vector system based on the use of adenovirus-transformed cells and a promoter, designated GBMT, capable of being activated by the Ela tumor antigen produced in these cells. GBMT-based vectors were constructed with hygromycin phosphotransferase and murine dihydrofolate reductase as selective markers. We demonstrate their utility in two adenovirus-transformed cell lines, human kidney 293 and Syrian hamster AV12-664. Further, we describe methods and conditions for the direct adaptation of isolated recombinant clones to serum-free suspension growth conditions. For exemplary purposes, we describe the generation of stable recombinant 293 cell lines with single-copy integrated vectors secreting the highly complex clotting factor human protein C at levels as high as 20 mg/l in serum-free suspension culture. In addition, using the AV12-664 cell line with GBMT and direct dominant selection of the dhfr gene, we have isolated clones secreting a tissue plasminogen activator derivative at levels of about 40 mg/l under serum-free suspension conditions. The distinct advantages of this vector/host cell system are 1) the direct selection of stable clones expressing relatively high levels of recombinant protein, eliminating the need for the tedious stepwise gene amplification process and 2) the direct adaptation to serum-free suspension culture.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8333965

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  12 in total

1.  Adaptation of mammalian cells to growth in serum-free media.

Authors:  M S Sinacore; D Drapeau; S R Adamson
Journal:  Mol Biotechnol       Date:  2000-07       Impact factor: 2.695

2.  Establishment of stable high expression cell line with green fluorescent protein and resistance genes.

Authors:  Shengtao Zhang; Wenli Liu; Peigen He; Feili Gong; Dongliang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Continuous production and recovery of recombinant Ca2+ binding receptor from HEK 293 cells using perfusion through a packed bed bioreactor.

Authors:  J B Kaufman; G Wang; W Zhang; M A Valle; J Shiloach
Journal:  Cytotechnology       Date:  2000-07       Impact factor: 2.058

4.  Pharmacological characterization of desensitization in a human mGlu1 alpha-expressing non-neuronal cell line co-transfected with a glutamate transporter.

Authors:  M A Desai; J P Burnett; N G Mayne; D D Schoepp
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

5.  Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.

Authors:  David T Berg; Bruce Gerlitz; Jing Shang; Tommy Smith; Paula Santa; Mark A Richardson; Ken D Kurz; Brian W Grinnell; Ken Mace; Bryan E Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

6.  Structure and function in rhodopsin: high level expression of a synthetic bovine opsin gene and its mutants in stable mammalian cell lines.

Authors:  P J Reeves; R L Thurmond; H G Khorana
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Identification of a region in protein C involved in thrombomodulin-stimulated activation by thrombin: potential repulsion at anion-binding site I in thrombin.

Authors:  B W Grinnell; B Gerlitz; D T Berg
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

8.  Rescue of influenza A virus from recombinant DNA.

Authors:  E Fodor; L Devenish; O G Engelhardt; P Palese; G G Brownlee; A García-Sastre
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  Optimizing the transient transfection process of HEK-293 suspension cells for protein production by nucleotide ratio monitoring.

Authors:  Maria de Los Milagros Bassani Molinas; Christiane Beer; Friedemann Hesse; Manfred Wirth; Roland Wagner
Journal:  Cytotechnology       Date:  2013-06-18       Impact factor: 2.058

10.  Development and improvement of a serum-free suspension process for the production of recombinant adenoviral vectors using HEK293 cells.

Authors:  Y S Tsao; R Condon; E Schaefer; P Lio; Z Liu
Journal:  Cytotechnology       Date:  2001-11       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.